Effects of CYP2C11 gene knockout on the pharmacokinetics and pharmacodynamics of warfarin in rats

References

• Agrawal AK, Shapiro BH. (2000). Differential expression of gender-dependent hepatic isoforms of cytochrome P-450 by pulse signals in the circulating masculine episodic growth hormone profile of the rat. J Pharmacol Exp Ther 292:228–37.
   PubMed Web of Science ®Google Scholar
• Am VDB. (1985). Standardization of the prothrombin time in oral anticoagulant control. Pathophysiol Haemost Thromb 15:271–7.
   Google Scholar
• Ansell J, Hirsh J, Poller L, et al. (2004). The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126:204S–33S.
   PubMed Web of Science ®Google Scholar
• Barbosa-Sicard E, Markovic M, Honeck H, et al. (2005). Eicosapentaenoic acid metabolism by cytochrome P450 enzymes of the CYP2C subfamily. Biochem Biophys Res Commun 329:1275–81.
   PubMed Web of Science ®Google Scholar
• Breckenridge A. (1978). Oral anticoagulant drugs: pharmacokinetic aspects. Semin Hematol 15:19.
   PubMed Web of Science ®Google Scholar
• Choi HK, Waxman DJ. (2000). Plasma growth hormone pulse activation of hepatic JAK-STAT5 signaling: developmental regulation and role in male-specific liver gene expression. Endocrinology 141:3245–55.
   PubMed Web of Science ®Google Scholar
• Ding XX, Coon MJ. (1990). Immunochemical characterization of multiple forms of cytochrome P-450 in rabbit nasal microsomes and evidence for tissue-specific expression of P-450s NMa and NMb. Mol Pharmacol 37:489.
   PubMed Web of Science ®Google Scholar
• Gonzalez FJ. (2003). Role of gene knockout and transgenic mice in the study of xenobiotic metabolism. Drug Metab Rev 35:319–35.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. (1977). Separation and purification of multiple forms of microsomal cytochrome P-450. Activities of different forms of cytochrome P-450 towards several compounds of environmental interest. J Biol Chem 252:3970.
   PubMed Web of Science ®Google Scholar
• Harumi T, Wilkinson GR, Yoseph C, et al. (2003). Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther 73:253.
   PubMed Web of Science ®Google Scholar
• Hermida J, Zarza J, Alberca I, et al. (2002). Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol. Blood 99:4237–9.
   PubMed Web of Science ®Google Scholar
• Hirsh J, Fuster V, Ansell J, Halperin JL. (2003). American heart association/American college of cardiology foundation guide to warfarin therapy. J Am Coll Cardiol 41:1633–52.
   PubMed Web of Science ®Google Scholar
• Kaminsky LS, Fasco MJ, Guengerich FP. (1979). Comparison of different forms of liver, kidney, and lung microsomal cytochrome P-450 by immunological inhibition of regio- and stereoselective metabolism of warfarin. J Biol Chem 254:9657.
   PubMed Web of Science ®Google Scholar
• Kaminsky LS, Zhang ZY. (1997). Human P450 metabolism of warfarin. Pharmacol Ther 73:67–74.
   PubMed Web of Science ®Google Scholar
• Karlgren M, Simoff I, Keiser M, et al. (2018). CRISPR-Cas9: a new addition to the drug metabolism and disposition tool box. Drug Metab Dispos 46:1776–86.
   PubMed Web of Science ®Google Scholar
• Kelly JG, Oʼmalley K. (1979). Clinical pharmacokinetics of oral anticoagulants. Clin Pharmacokinet 4:1–15.
   PubMed Web of Science ®Google Scholar
• Lang D, Böcker R. (1995). Highly sensitive and specific high-performance liquid chromatographic analysis of 7-hydroxywarfarin, a marker for human cytochrome P-4502C9 activity. J Chromatogr B Biomed Appl 672:305–9.
   PubMed Web of Science ®Google Scholar
• Loeliger EA, Am VDB, Lewis SM. (1985a). Reliability and clinical impact of the normalization of the prothrombin times in oral anticoagulant control. Thromb Haemost 53:148–54.
   PubMed Web of Science ®Google Scholar
• Loeliger EA, Poller L, Samama M, et al. (1985b). Questions and answers on prothrombin time standardisation in oral anticoagulant control. Thromb Haemost 53:515–7.
   Google Scholar
• Maria Gabriella S, Vittorio P, Edoardo S, et al. (2002). Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 72:702.
   PubMed Web of Science ®Google Scholar
• Martignoni M, Groothuis GM, De KR. (2006). Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875–94.
   PubMed Web of Science ®Google Scholar
• Mckinnon RA, Nebert DW. (2010). Cytochrome P450 knockout mice: new toxicological models. Clin Exp Pharmacol Physiol 25:783–7.
   Web of Science ®Google Scholar
• Miners JO, Birkett DJ. (1998). Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525–38.
   PubMed Web of Science ®Google Scholar
• O’Reilly RA. (1976). Vitamin K and the oral anticoagulant drugs. Annu Rev Med 27:245.
   PubMed Web of Science ®Google Scholar
• O’Reilly RA. (1987). Warfarin metabolism and drug-drug interactions. The new dimensions of warfarin prophylaxis. New York, USA: Springer.
   Google Scholar
• Rahmaniyan M, Patrick K, Bell NH. (2005). Characterization of recombinant CYP2C11: a vitamin D 25-hydroxylase and 24-hydroxylase. Am J Physiol Endocrinol Metab 288:E753.
   PubMed Web of Science ®Google Scholar
• Redman AR. (2001). Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing. Pharmacotherapy 21:235–42.
   PubMed Web of Science ®Google Scholar
• Roman RJ. (2002). P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82:131.
   PubMed Web of Science ®Google Scholar
• Ryan DE, Levin W. (1990). Purification and characterization of hepatic microsomal cytochrome P-450. Pharmacol Ther 45:153–239.
   PubMed Web of Science ®Google Scholar
• Scheer N, Kapelyukh Y, Chatham L, et al. (2012). Generation and characterization of novel cytochrome P450 Cyp2c gene cluster knockout and CYP2C9 humanized mouse lines. Mol Pharmacol 82:1022–9.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Kashima T, Nomoto S, et al. (1998). Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics 8:365.
   PubMedGoogle Scholar
• Tomalik-Scharte D, Lazar A, Fuhr U, Kirchheiner J. (2008). The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J 8:4.
   PubMed Web of Science ®Google Scholar
• van Waterschoot RA, van Herwaarden AE, Lagas JS, et al. (2008). Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes. Mol Pharmacol 73:1029–36.
   PubMed Web of Science ®Google Scholar
• Wang X, Lee WY, Or PM, Yeung JH. (2010). Pharmacokinetic interaction studies of tanshinones with tolbutamide, a model CYP2C11 probe substrate, using liver microsomes, primary hepatocytes and in vivo in the rat. Phytomedicine 17:203–11.
   PubMed Web of Science ®Google Scholar
• Wei Y, Yang L, Zhang X, et al. (2018). Generation and characterization of a CYP2C11-null rat model by using the CRISPR/Cas9 method. Drug Metab Dispos 46:525–31.
   PubMed Web of Science ®Google Scholar
• Wu WW, Yeung JH. (2010). Inhibition of warfarin hydroxylation by major tanshinones of Danshen (Salvia miltiorrhiza) in the rat in vitro and in vivo. Phytomedicine 17:219–26.
   PubMed Web of Science ®Google Scholar
• Xuan Z, Lee DY, Wan GS. (2010). Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. Biopharm Drug Dispos 28:125–33.
   Google Scholar
• Zhou Q, Zhou S, Chan E. (2005). Effect of coenzyme Q10 on warfarin hydroxylation in rat and human liver microsomes. Curr Drug Metab 6:67–81.
   Web of Science ®Google Scholar